These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33911107)

  • 1. Evaluation of digital dispense-assisted broth microdilution antimicrobial susceptibility testing for Pseudomonas aeruginosa isolates.
    Clark ST; Stapleton PJ; Wang PW; Yau YCW; Waters VJ; Hwang DM; Guttman DS
    Sci Rep; 2021 Apr; 11(1):9157. PubMed ID: 33911107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Inoculum Effect in the Era of Multidrug Resistance: Minor Differences in Inoculum Have Dramatic Effect on MIC Determination.
    Smith KP; Kirby JE
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
    Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents.
    Sader HS; Fritsche TR; Jones RN
    J Clin Microbiol; 2006 Mar; 44(3):1101-4. PubMed ID: 16517904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
    Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
    Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of different methods of determining beta-lactam susceptibility in clinical strains of Pseudomonas aeruginosa.
    Torres E; Villanueva R; Bou G
    J Med Microbiol; 2009 May; 58(Pt 5):625-629. PubMed ID: 19369524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Performance evaluation of VITEK 2 system in meropenem susceptibility testing of clinical Pseudomonas aeruginosa isolates].
    Acuner IC; Bayramoğlu G; Birinci A; Cekiç Cihan C; Bek Y; Durupınar B
    Mikrobiyol Bul; 2011 Jul; 45(3):411-21. PubMed ID: 21935774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of Aztreonam-Avibactam Susceptibility Testing Using Digitally Dispensed Custom Panels.
    Ransom E; Bhatnagar A; Patel JB; Machado MJ; Boyd S; Reese N; Lutgring JD; Lonsway D; Anderson K; Brown AC; Elkins CA; Rasheed JK; Karlsson M
    J Clin Microbiol; 2020 Mar; 58(4):. PubMed ID: 32051259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactam.
    Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA
    Int J Antimicrob Agents; 2019 Aug; 54(2):255-260. PubMed ID: 31071465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reproducibility between two readout methods of a commercial broth microdilution assay for Pseudomonas aeruginosa isolates from patients with Cystic Fibrosis.
    Franssens BT; Fluit AC; Rentenaar RJ
    Infect Dis (Lond); 2019 Jan; 51(1):50-55. PubMed ID: 30654670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of Vitek 2 in antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates with different mechanisms of beta-lactam resistance.
    Mazzariol A; Aldegheri M; Ligozzi M; Lo Cascio G; Koncan R; Fontana R
    J Clin Microbiol; 2008 Jun; 46(6):2095-8. PubMed ID: 18434562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.
    van der Heijden IM; Levin AS; De Pedri EH; Fung L; Rossi F; Duboc G; Barone AA; Costa SF
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():8. PubMed ID: 17697363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa.
    Bailey AL; Armstrong T; Dwivedi HP; Denys GA; Hindler J; Campeau S; Traczewski M; Humphries R; Burnham CA
    J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 29976590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colistin susceptibility test evaluation of multiple-resistance-level Pseudomonas aeruginosa isolates generated in a morbidostat device.
    Javed M; Ueltzhoeffer V; Heinrich M; Siegrist HJ; Wildermuth R; Lorenz FR; Neher RA; Willmann M
    J Antimicrob Chemother; 2018 Dec; 73(12):3368-3374. PubMed ID: 30137346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis.
    Lasko MJ; Huse HK; Nicolau DP; Kuti JL
    Ann Clin Microbiol Antimicrob; 2021 Jan; 20(1):9. PubMed ID: 33468149
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Etest and disk diffusion method for detection of the activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa in China.
    Wang Q; Zhang F; Wang Z; Chen H; Wang X; Zhang Y; Li S; Wang H
    BMC Microbiol; 2020 Jun; 20(1):187. PubMed ID: 32600252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014-2017 and 2018.
    Kristóf K; Adámková V; Adler A; Gospodarek-Komkowska E; Rafila A; Billová S; Możejko-Pastewka B; Kiss F
    Diagn Microbiol Infect Dis; 2021 Sep; 101(1):115420. PubMed ID: 34091111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.